Abstract
In this preliminary report, PCR positivity data in the second wave of the COVID pandemic (September-January 2020) are shown to obey a scaling law given by:
where % P0 and Σ0 are the y- and x-intercepts of a plot of positivity, %P, against the number of tests, Σ. The law holds across international, regional and local boundaries, as demonstrated for Great Britain, Austria, Germany and Sweden, the nine English regions, London - Yorkshire & Humber, and various Local Health Authorities in England. One possible explanation for scaling might be Dorfman pooling.
The scaling law can be used to remove a systematic or false positive (FP) component from the daily number of positive tests, or cases, to yield the real number of cases. The results correlate strongly with the ZOE survey for London (R2=0.787) and Excess Deaths for England (R2=0.833). The cumulative total of FPs can be estimated as 1.4M by the beginning of 2021, in line with other estimates.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request from the author
